Thursday, January 28, 2010
NellOne Therapeutics licenses from UT-Battelle
Knoxville-based NellOne Therapeutics has licensed patents covering inventions based on the Nell-1 gene. The IP is driving protein therapy treatment now under development and takes advantage of the gene's cell-signaling pathway, which controls tissue growth and maturation in mammalian organs. It could mean restorative therapies for hearts and other muscles. Our story's here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment